Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2013, Quick Ratio deteriorated to 2.37 above company average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 44 other companies have achieved higher Quick Ratio than Gentium S.p.a. in fourth quarter 2013. While Quick Ratio total ranking has improved so far during the Q4 2013 to 867, from total ranking in the third quarter 2013 at 1056.

Explain Quick Ratio?
How much Cash & cash equivalents GENT�s has?
What are GENT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GENT Quick Ratio	(Dec 31 2013) Q4	0 Q3	(Jun 30 2013) Q2	0 Q1	(Dec 31 2012) FY
Y / Y Current Liabilities Change	5.39 %	-22.92 %	10.39 %	-27.84 %	-
Y / Y Cash & cash equivalent Change	-1.88 %	23.54 %	62.16 %	35.19 %	-
Quick Ratio MRQ	2.37	2.37	2.41	2.37	2.55
GENT's Total Ranking	# 867	# 1056	# 1060	# 918	# 885
Seq. Current Liabilities Change	0 %	-22.04 %	28.27 %	5.39 %	-26.86 %
Seq. Cash & cash equivalent Change	0 %	-23.14 %	30.1 %	-1.88 %	25.9 %

Quick Ratio fourth quarter 2013 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 45
Healthcare Sector	# 268
Overall Market	# 867

Quick Ratio Statistics
High	Average	Low
2.48	2.25	1.56
(Dec 31 2012)		(Dec 31 2011)

Financial Statements
Gentium S.p.a.'s Current Liabilities	$ 7 Millions	Visit GENT's Balance sheet
Gentium S.p.a.'s Cash & cash equivalent	$ 16 Millions	Visit GENT's Balance sheet
Source of GENT's Sales		Visit GENT's Sales by Geography

Cumulative Gentium S.p.a.'s Quick Ratio

GENT's Quick Ratio for the trailling 12 Months

GENT Quick Ratio	(Dec 31 2013) 12 Months	0 12 Months	(Jun 30 2013) 12 Months	0 12 Months	(Dec 31 2012) 12 Months
Y / Y Current Liabilities TTM Growth	-10.66 %	10.05 %	77.76 %	218.1 %	-
Y / Y Cash & cash equivalent TTM Growth	27.61 %	83.72 %	167.81 %	390.87 %	-
Quick Ratio TTM	2.38	2.42	2.16	1.95	1.67
Total Ranking TTM	# 374	# 0	# 0	# 0	# 0
Seq. Current Liabilities TTM Growth	1.21 %	-6.56 %	2.74 %	-8.05 %	24.68 %
Seq. Cash & cash equivalent TTM Growth	-0.44 %	4.61 %	13.74 %	7.72 %	43.34 %

Quick ratio ranking by company, industry and sector >> Back to GENT Financial Strength Comparisons >> Go to Compare GENT Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2013 to $6.81 millions, cumulative Quick Ratio decreased to 2.38 above the GENT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 23 other companies have achieved higher Quick Ratio than Gentium S.p.a.. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2013 from 0 to 374.

Explain Quick Ratio?
How much Cash & cash equivalents GENT�s has?
What are GENT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 24
Healthcare Sector	# 89
Within the Market	# 374

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.85	1.85	1.85
0

Companies with similar Quick Ratio in the quarter ending Dec 31 2013, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2013 MRQ Cash & cash equivalent	Dec 31 2013 MRQ Current Liabilities
Telik Inc	6.12	$ 2.229 Millions	$ 0.364 Millions
Sorrento Therapeutics Inc	5.78	$ 31.667 Millions	$ 5.480 Millions
Repligen Corp	5.45	$ 61.623 Millions	$ 11.301 Millions
Vaxart Inc	5.18	$ 66.800 Millions	$ 12.900 Millions
Viskase Holdings inc	4.98	$ 6.520 Millions	$ 1.308 Millions
Receptos, Inc.	4.31	$ 69.490 Millions	$ 16.141 Millions
Acceleron Pharma inc	4.19	$ 114.076 Millions	$ 27.210 Millions
Qiagen N v	3.91	$ 472.473 Millions	$ 120.834 Millions
Pluri Inc	3.84	$ 22.764 Millions	$ 5.921 Millions
Seagen Inc	3.77	$ 374.267 Millions	$ 99.198 Millions
Champions Oncology Inc	3.26	$ 9.561 Millions	$ 2.929 Millions
Cellular Biomedicine Group Inc	3.26	$ 7.175 Millions	$ 2.202 Millions
Genocea Biosciences Inc	3.24	$ 12.365 Millions	$ 3.813 Millions
Protalix Biotherapeutics inc	3.24	$ 86.398 Millions	$ 26.696 Millions
Exelixis Inc	2.90	$ 254.666 Millions	$ 87.853 Millions
Palisade Bio Inc	2.84	$ 16.846 Millions	$ 5.936 Millions
Acorda Therapeutics Inc	2.84	$ 274.205 Millions	$ 96.643 Millions
Halozyme Therapeutics Inc	2.81	$ 71.503 Millions	$ 25.453 Millions
Agenus Inc	2.66	$ 27.352 Millions	$ 10.296 Millions
Brainstorm Cell Therapeutics inc	2.63	$ 3.503 Millions	$ 1.332 Millions
Biocryst Pharmaceuticals Inc	2.50	$ 38.206 Millions	$ 15.256 Millions
Amgen Inc	2.44	$ 19,401.000 Millions	$ 7,947.000 Millions
Gentium S.p.a.	2.37	$ 16.154 Millions	$ 6.808 Millions
Nanostring Technologies Inc	2.29	$ 42.656 Millions	$ 18.630 Millions
Eiger Biopharmaceuticals Inc	2.25	$ 10.612 Millions	$ 4.713 Millions
Cannabis Global Inc.	1.91	$ 0.011 Millions	$ 0.006 Millions
Dendreon Corp	1.73	$ 179.622 Millions	$ 103.761 Millions
Cadence Pharmaceuticals Inc	1.59	$ 57.949 Millions	$ 36.543 Millions
Vericel Corporation	1.51	$ 8.059 Millions	$ 5.321 Millions
Coherus Oncology inc	1.48	$ 39.604 Millions	$ 26.703 Millions

Date modified: 2026-09-10T02:29:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.